Literature DB >> 8713459

Neurotensin excitation of serotonergic neurons in the dorsal raphe nucleus of the rat in vitro.

T Jolas1, G K Aghajanian.   

Abstract

Neurotensin-containing terminals and radioligand binding sites are present in the dorsal raphe nucleus. The purpose of this study was to test, in brain slices containing this nucleus, the effect of neurotensin on the electrical activity of serotonergic neurons. In extracellular recordings, the cells were identified by the ability of the alpha 1-adrenoceptor agonist phenylephrine to induce firing, and serotonin to reduce this effect. After washout of phenylephrine, neurotensin (10 nM to 10 microM) induced a concentration-dependent increase in the firing rate of serotonergic neurons (EC50 = 142 nM; maximum effect approximately 1 microM). The neurotensin excitation, which was mimicked by neurotensin fragments 8-13 but not neurotensin peptide fragment 1-8 and selectively blocked by SR 48692 (100 nM), was observed mainly in the ventral part of the nucleus. Most serotonergic neurons showed marked desensitization to neurotensin, even at low concentrations. The neurotensin response was occluded by supramaximal concentrations of phenylephrine. In intracellular recordings using KCl-containing electrodes, neurotensin induced an inward current associated in some cases with a decrease in apparent input conductance. In conclusion, neurotensin was found to have an excitatory action on serotonergic neurons in the ventral part of the dorsal raphe nucleus, an effect which could be subject to desensitization and was occluded by phenylephrine. This occlusion phenomenon may be important for the physiological role of neurotensin in the dorsal raphe nucleus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8713459     DOI: 10.1111/j.1460-9568.1996.tb01176.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  9 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

2.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Eur J Neurosci       Date:  2018-02-28       Impact factor: 3.386

3.  Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine.

Authors:  C Betancur; R Cabrera; E R de Kloet; D Pélaprat; W Rostène
Journal:  Neuropsychopharmacology       Date:  1998-10       Impact factor: 7.853

4.  Neurotensin induces hypothermia by activating both neuronal neurotensin receptor 1 and astrocytic neurotensin receptor 2 in the median preoptic nucleus.

Authors:  Iustin V Tabarean
Journal:  Neuropharmacology       Date:  2020-04-08       Impact factor: 5.250

5.  Hypocretin (orexin) enhances neuron activity and cell synchrony in developing mouse GFP-expressing locus coeruleus.

Authors:  Anthony N van den Pol; Prabhat K Ghosh; Rong-Jian Liu; Ying Li; George K Aghajanian; Xiao-Bing Gao
Journal:  J Physiol       Date:  2002-05-15       Impact factor: 5.182

6.  Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy.

Authors:  Mei Yin; Yeo-Ok Kim; Jeong-Il Choi; Seongtae Jeong; Si-Ho Yang; Hong-Beom Bae; Myung-Ha Yoon
Journal:  Korean J Pain       Date:  2020-10-01

7.  Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist.

Authors:  P D Shilling; G Melendez; K Priebe; E Richelson; D Feifel
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

8.  Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey.

Authors:  V A Mitchell; H Kawahara; C W Vaughan
Journal:  J Physiol       Date:  2009-04-09       Impact factor: 5.182

9.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.